**FIGURE 1**

```
MGTVNKPVVG VLMGFGIITG TLRITNPVRA SVLRYDDFHI DEDKLDTNSV YEPYYHSDHA 60
ESSWVNRGES SRKAYDHNSP YIWPRNDYDG FLENAHEHHG VYNQGRGIDS GERLMQPTQM 120
SAQEDLGDDT GIHVIPTLNG DDRHKIVNVD QRQYGDVFKG DLNPKPQGQR LIEVSVEENH 180
PFTLRAPIQR IYGVRYTETW SFLPSLTCTG DAAPAIQHIC LKHTTCFQDV VVDVDCAENT 240
KEDQLAEISY RFQGKKEADQ PWIVVNTSTL FDELELDPPE IEPGVLKVLR TEKQYLGVYI 300
WNMRGSDGTS TYATFLVTWK GDEKTRNPTP AVTPQPRGAE FHMWNYHSHV FSVGDTFSLA 360
MHLQYKIHEA PFDLLLEWLY VPIDPTCQPM RLYSTCLYHP NAPQCLSHMN SGCTFTSPHL 420
AQRVASTVYQ NCEHADNYTA YCLGISHMEP SFGLILHDGG TTLKFVDTPE SLSGLYVFVV 480
YFNGHVEAVA YTVVSTVDHF VNAIEERGFP PTAGQPPATT KPKEITPVNP GTSPLIRYAA 540
WTGGLA 546
```

**FIGURE 2**

```
MGTVNKPVVG VLMGFGIITG TLRITNPVRA SVLRYDDFHT DEDKLDTNSV YEPYYHSDHA  60
ESSWVNRGES SRKAYDHNSP YIWPRNDYDG FLENAHEHHG VYNQGRGIDS GERLMQPTQM 120
SAQEDLGDDT GIHVIPTLNG DDRHKIVNVD QRQYGDVFKG DLNPKPQGQR LIEVSVEENH 180
PFTLRAPIQR IYGVRYTETW SFLPSLTCTG DAAPAIQHIC LKHTTCFQDV VVDVDCAENT 240
KEDQLAEISY RFQGKKEADQ PWIVVNTSTL FDELELDPPE IEPGVLKVLR TEKQYLGVYI 300
WNMRGSDGTS TYATFLVTWK GDEKTRNPTP AVTPQPRGAE FHMWNYHSHV FSVGDTFSLA 360
MHLQYKIHEA PFDLLLEWLY VPIDPTCQPM RLYSTCLYHP NAPQCLSHMN SGCTFTSPHL 420
AQRVASTVYQ NCEHADNYTA YCLGISHMEP SFGLILHDGG TTLKFVDTPE SLSGLYVFVV 480
YFNGHVEAVA YTVVSTVDHF VNAIEERGFP PTAGQPPATT KPKEITPVNP GTSPLLRYAA 540
WTGGLA                                                          546
```

**FIGURE 3**

```
MGTVNKPVVG VLMGFGIITG TLRITNPVRA SVLRYDDFHT DEDKLDTNSV YEPYYHSDHA 60
ESSWVNRGES SRKAYDHNSP YIWPRNDYDG FLENAHEHHG VYNQGRGIDS GERLMQPTQM 120
SAQEDLGDDT GIHVIPTLNG DDRHKIVNVD QRQYGDVFKG DLNPKPQGQR LIEVSVEENH 180
PFTLRAPIQR IYGVRYTETW SFLPSLTCTG DAAPAIQHIC LKHTTCFQDV VVDVDCAENT 240
KEDQLAEISY RFQGKKEADQ PWIVVNTSTL FDELELDPPE IEPGVLKVLR TEKQYLGVYI 300
WNMRGSDGTS TYATFLVTWK GDEKTRNPTP AVTPQPRGAE FHMWNYHSHV FSVGDTFSLA 360
MHLQYKIHEA PFDLLLEWLY VPIDPTCQPM RLYSTCLYHP NAPQCLSHMN SGCTFTSPHL 420
AQRVASTVYQ NCEHADNYTA YCLGISHMEP SFGLILHDGG TTLKFVDTPE SLSGLYVFVV 480
YFNGHVEAVA YTVVSTVDHF VNAIEERGFP PTAGQPPATT KPKEITPVNP GTSPLLRYAA 540
WTGGLAAVVL LCLVIFLICT AKRMRVKAYR VDKSPYNQSM YYAGLPVDDF EDSESTDTEE 600
EFGNAIGGSH GGSSYTVYID KTR 623
```

**FIGURE 4**

MGTVNKPVVG VLMGFGIITG TLRITNPVRA SVLRYDDFHT DEDKLDTNSV YEPYYHSDHA 60

ESSWVNRGES SRKAYDHNSP YIWPRNDYDG FLENAHEHHG VYNQGRGIDS GERLMQPTQM 120

SAQEDLGDDT GIHVIPTLNG DDRHKIVNVD QRQYGDVFKG DLNPKPQGQR LIEVSVEENH 180

PFTLRAPIQR IYGVRYTETW SFLPSLTCTG DAAPAIQHIC LKHTTCFQDV VVDVDCAENT 240

KEDQLAEISY RFQGKKEADQ PWIVVNTSTL FDELELDPPE IEPGVLKVLR TEKQYLGVYI 300

WNMRGSDGTS TYATFLVTWK GDEKTRNPTP AVTPQPRGAE FHMWNYHSHV FSVGDTFSLA 360

MHLQYKIHEA PFDLLLEWLY VPIDPTCQPM RLYSTCLYHP NAPQCLSHMN SGCTFTSPHL 420

AQRVASTVYQ NCEHADNYTA YCLGISHMEP SFGLILHDGG TTLKFVDTPE SLSGLYVFVV 480

YFNGHVEAVA YTVVSTVDHF VNAIEERGFP PTAGQPPATT KPKEITPVNP GTSPLIRYAA 540

WTGGLAAVVL LCLVIFLICT AKRMRVKAYR VDKSPYNQSM YYAGLPVDDF EDSESTDTEE 600

EFGNAIGGSH GGSSYTVYID KTR 623

**FIGURE 5**

| | | | | | | |
|---|---|---|---|---|---|---|
| MSPCGYYSKW | RNRDRPEYRR | NLRFRRFFSS | IHPNAAAGSG | FNGPGVFITS | VTGVWLCFLC | 60 |
| IFSMFVTAVV | SVSPSSFYES | LQVEPTQSED | ITRSAHLGDG | DEIREAIHKS | QDAETKPTFY | 120 |
| VCPPPTGSTI | VRLEPPRTCP | DYHLGKNFTE | GIAVVYKENI | AAYKFKATVY | YKDVIVSTAW | 180 |
| AGSSYTQITN | RYADRVPIPV | SEITDTIDKF | GKCSSKATYV | RNNHKVEAFN | EDKNPQDMPL | 240 |
| IASKYNSVGS | KAWHTTNDTY | MVAGTPGTYR | TGTSVNCIIE | EVEARSIFPY | DSFGLSTGDI | 300 |
| IYMSPFFGLR | DGAYREHSNY | AMDRFHQFEG | YRQRDLDTRA | LLEPAARNFL | VTPHLTVGWN | 360 |
| WKPKRTEVCS | LVKWREVEDV | VRDEYAHNFR | FTMKTLSTTF | ISETNEFNLN | QIHLSQCVKE | 420 |
| EARAIINRIY | TTRYNSSHVR | TGDIQTYLAR | GGFVVVFQPL | LSNSLARLYL | QELVRENTNH | 480 |
| SPQKHPTRNT | RSRRSVPVEL | RANRTITTTS | SVEFAMLQFT | YDHIQEHVNE | MLARISSSWC | 540 |
| QLQNRERALW | SGLFPINPSA | LASTILDQRV | KARILGDVIS | VSNCPELGSD | TRIILQNSMR | 600 |
| VSGSTTRCYS | RPLISIVSLN | GSGTVEGQLG | TDNELIMSRD | LLEPCVANHK | RYFLFGHHYV | 660 |
| YYEDYRYVRE | IAVHDVGMIS | TYVDLNLTLL | KDREFMPLQV | YTRDELRDTG | LLDYSEIQRR | 720 |
| NQMHSLRFYD | IDKVVQYDSG | TAIMQGMAQF | FQGLGTAGQA | VGHVVLGATG | ALLSTVHGFT | 780 |
| TFLSNPFGAL | AVGLLVLAGL | VAAFFAYRYV | LKLKTSPMKA | LYPLTTKGLK | QLPEGMDPFA | 840 |
| EKPNATDTPI | EEIGDSQNTE | PSVNSGFDPD | KFREAQEMIK | YMTLVSAAER | QESKARKKNK | 900 |
| TSALLTSRLT | GLALRNRRGY | SRVRTENVTG | V | | | 931 |

**FIGURE 6**

MFALVLAVVI LPLWTTANKS YVTPTPATRS IGHMSALLRE YSDRNMSLKL EAFYPTGFDE 60

ELIKSLHWGN DRKHVFLVIV KVNPTTHEGD VGLVIFPKYL LSPYHFKAEH RAPFPAGRFG 120

FLSHPVTPDV SFFDSSFAPY LTTQHLVAFT TFPPNPLVWH LERAETAATA ERPFGVSLLP 180

ARPTVPKNTI LEHKAHFATW DALARHTFFS AEAIITNSTL RIHVPLFGSV WPIRYWATGS 240

VLLTSDSGRV EVNIGVGFMS SLISLSSGLP IELIVVPHTV KLNAVTSDTT WFQLNPPGPD 300

PGPSYRVYLL GRGLDMNFSK HATVDICAYP EESLDYRYHL SMAHTEALRM TTKADQHDIN 360

EESYYHIAAR IATSIFALSE MGRTTEYFLL DEIVDVQYQL KFLNYILMRI GAGAHPNTIS 420

GTSDLIFADP SQLHDELSLL FGQVKPANVD YFISYDEARD QLKTAYALSR GQDHVNALSL 480

ARRVIMSIYK GLLVKQNLNA TERQALFFAS MILLNFREGL ENSSRVLDGR TTLLLMTSMC 540

TAAHATQAAL NIQEGLAYLN PSKHMFTIPN VYSPCMGSLR TDLTEEIHVM NLLSAIPTRP 600

GLNEVLHTQL DESEIFDAAF KTMMIFTTWT AKDLHILHTH VPEVFTCQDA AARNGEYVLI 660

LPAVQGHSYV ITRNKPQRGL VYSLADVDVY NPISVVYLSK DTCVSEHGVI ETVALPHPDN 720

LKECLYCGSV FLRYLTTGAI MDIIIIDSKD TERQLAAMGN STIPPFNPDM HGDDSKAVLL 780

FPNGTVVTLL GFERRQAIRM SGQYLGASLG GAFLAVVGFG IIGWMLCGNS RLREYNKIPL 840

T 841

**FIGURE 7**

MFLIQCLISA VIFYIQVTNA LIFKGDHVSL QVNSSLTSIL IPMQNDNYTE IKGQLVFIGE 60

QLPTGTNYSG TLELLYADTV AFCFRSVQVI RYDGCPRIRT SAFISCRYKH SWHYGNSTDR 120

ISTEPDAGVM LKITKPGIND AGVYVLLVRL DHSRSTDGFI LGVNVYTAGS HHNIHGVIYT 180

SPSLQNGYST RALFQQARLC DLPATPKGSG TSLFQHMLDL RAGKSLEDNP WLHEDVVTTE 240

TKSVVKEGIE NHVYPTDMST LPEKSLNDPP ENLLIIIPIV ASVMILTAMV IVIVISVKRR 300

RIKKHPIYRP NTKTRRGIQN ATPESDVMLE AAIAQLATIR EESPPHSVVN PFVK 354

**FIGURE 8**

| | | | | | | |
|---|---|---|---|---|---|---|
| MSKKTFPSFK | FRGGCFNLLF | KGSVDVSIKT | RMKRIQINLI | LTIACIQLST | ESQPTPVSIT | 60 |
| ELYTSAATRK | PDPAVAPTSA | ASRKPDPAVA | PTSAASRKPD | PAVAPTSAAS | RKPDPAVAPT | 120 |
| SAATRKPDPA | VAPTSAASRK | PDPAVAPTSA | ATRKPDPAVA | PTSAASRKPD | PAANTQHSQP | 180 |
| PFLYENIQCV | HGGIQSIPYF | HTFIMPCYMR | LTTGQQAAFK | QQQKTYEQYS | LDPEGSNITR | 240 |
| WKSLIRPDLH | IEVWFTRHLI | DPHRQLGNAL | IRMPDLPVML | YSNSADLNLI | NNPEIFTHAK | 300 |
| ENYVIPDVKT | TSDFSVTILS | MDATTEGTYI | WRVVNTKTKN | VISEHSITVT | TYYRPNITVV | 360 |
| GDPVLTGQTY | AAYCNVSKYY | PPHSVRVRWT | SRFGNIGKNF | ITDAIQEYAN | GLFSYVSAVR | 420 |
| IPQQKQMDYP | PPAIQCNVLW | IRDGVSNMKY | SAVVTPDVYP | FPNVSIGIID | GHIVCTAKCV | 480 |
| PRGVVHFVWW | VNDSPINHEN | SEITGVCDQN | KRFVNMQSSC | PTSELDGPIT | YSCHLDGYPK | 540 |
| KFPPFSAVYT | YDASTYATTF | SVVAVIIGVI | SILGTLGLIA | VIATLCIRCC | S | 591 |

**FIGURE 9**

| | | | | | | |
|---|---|---|---|---|---|---|
| MGVKVLFALI | CIAVAEASVL | RYDDFHIDED | KLDTNSVYEP | YYHSDHAESS | WVNRGESSRK | 60 |
| AYDHNSPYIW | PRNDYDGFLE | NAHEHHGVYN | QGRGIDSGER | LMQPTQMSAQ | EDLGDDTGIH | 120 |
| VIPTLNGDDR | HKIVNVDQRQ | YGDVFKGDLN | PKPQGQRLIE | VSVEENHPFT | LRAPIQRIYG | 180 |
| VRYTETWSFL | PSLTCTGDAA | PAIQHICLKH | TTCFQDVVVD | VDCAENTKED | QLAEISYRFQ | 240 |
| GKKEADQPWI | VVNTSTLFDE | LELDPPEIEP | GVLKVLRTEK | QYLGVYIWNM | RGSDGTSTYA | 300 |
| TFLVTWKGDE | KTRNPTPAVT | PQPRGAEFHM | WNYHSHVFSV | GDTFSLAMHL | QYKIHEAPFD | 360 |
| LLLEWLYVPI | DPTCQPMRLY | STCLYHPNAP | QCLSHMNSGC | TFTSPHLAQR | VASTVYQNCE | 420 |
| HADNYTAYCL | GISHMEPSFG | LILHDGGTTL | KFVDTPESLS | GLYVFVVYFN | GHVEAVAYTV | 480 |
| VSTVDHFVNA | IEERGFPPTA | GQPPATTKPK | EITPVNPGTS | PLIRYAAWTG | GLA | 533 |

FIGURE 10



Post Dose 1 (Day 14)
Endpoint Titer
1000000
100000
10000
1000
100
5 μg gE Alone
5 μg gE + Blank Liposome
5 μg gE + 7.5 μg PHAD/5 μg TQL1055
5 μg gE + 7.5 μg PHAD/15 μg TQL1055
5 μg gE + 7.5 μg PHAD/30 μg TQL1055
5 μg gE + 7.5 μg PHAD/50 μg TQL1055
5 μg gE + 7.5 μg MPL + 5 μg QS-21

FIGURE 11



Post Dose 2 (Day 28)
Endpoint Titer
1000000
100000
10000
1000
100
5 μg gE Alone
5 μg gE + Blank Liposome
5 μg gE + 7.5 μg PHAD/5 μg TQL1055
5 μg gE + 7.5 μg PHAD/15 μg TQL1055
5 μg gE + 7.5 μg PHAD/30 μg TQL1055
5 μg gE + 7.5 μg PHAD/50 μg TQL1055
5 μg gE + 7.5 μg MPL + 5 μg QS-21

FIGURE 12



Post Dose 1 (Day 14) IgG1
Endpoint Titer
1000000
100000
10000
1000
100
5 μg gE Alone
5 μg gE + Blank Liposome
5 μg gE + 7.5 μg PHAD/5 μg TQL1055
5 μg gE + 7.5 μg PHAD/15 μg TQL1055
5 μg gE + 7.5 μg PHAD/30 μg TQL1055
5 μg gE + 7.5 μg PHAD/50 μg TQL1055
5 μg gE + 7.5 μg MPL + 5 μg QS-21

FIGURE 13



Post Dose 2 (Day 28) IgG1
Endpoint Titer
1000000
100000
10000
1000
100
5 μg gE Alone
5 μg gE + Blank Liposome
5 μg gE + 7.5 μg PHAD/5 μg TQL1055
5 μg gE + 7.5 μg PHAD/15 μg TQL1055
5 μg gE + 7.5 μg PHAD/30 μg TQL1055
5 μg gE + 7.5 μg PHAD/50 μg TQL1055
5 μg gE + 7.5 μg MPL + 5 μg QS-21

FIGURE 14



Post Dose 1 (Day 14) IgG2c
Endpoint Titer
1000000
100000
10000
1000
100
5 μg gE Alone
5 μg gE + Blank Liposome
5 μg gE + 7.5 μg PHAD/5 μg TQL1055
5 μg gE + 7.5 μg PHAD/15 μg TQL1055
5 μg gE + 7.5 μg PHAD/30 μg TQL1055
5 μg gE + 7.5 μg PHAD/50 μg TQL1055
5 μg gE + 7.5 μg MPL + 5 μg QS-21

FIGURE 15



Post Dose 2 (Day 28) IgG2c
Endpoint Titer
1000000
100000
10000
1000
100
5 μg gE Alone
5 μg gE + Blank Liposome
5 μg gE + 7.5 μg PHAD/5 μg TQL1055
5 μg gE + 7.5 μg PHAD/15 μg TQL1055
5 μg gE + 7.5 μg PHAD/30 μg TQL1055
5 μg gE + 7.5 μg PHAD/50 μg TQL1055
5 μg gE + 7.5 μg MPL + 5 μg QS-21

FIGURE 16



Anti-gE IgG Endpoint Titers
Post Dose 1
Reciprocal Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
$10^3$
$10^2$
$10^1$
5 µg gE alone
5 µg gE + 5 µg PHAD liposome
5 µg gE + 5 µg PHAD liposome + 5 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 10 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 20 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 40 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 80 µg 1055 CS
5 µg gE + 5 µg 1055 CS
5 µg gE + 10 µg 1055 CS
5 µg gE + 20 µg 1055 CS
5 µg gE + 40 µg 1055 CS
5 µg gE + 80 µg 1055 CS

FIGURE 17A



5 µg 1055 C.S + PHAD Liposomes
Dose 1
Reciprocal Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
$10^3$
$10^2$
$10^1$
***
***
5 µg gE + 5 µg PHAD liposome
5 µg gE + 5 µg 1055 CS
5 µg gE + 5 µg 1055 CS + 5 µg PHAD

FIGURE 17B



10 µg 1055 C.S + PHAD Liposomes
Dose 1
Reciprocal Titer
(1/dilution)
10^7
10^6
10^5
10^4
10^3
10^2
10^1
5 µg gE + 5 µg PHAD
5 µg gE + 10 µg 1055 CS
5 µg gE + 5 µg PHAD + 10 µg 1055 CS

FIGURE 17C



20 µg 1055 C.S + PHAD Liposomes
Dose 1
Reciprocal Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
$10^3$
$10^2$
$10^1$
**
**
5 µg gE + 5 µg PHAD
5 µg gE + 20 µg 1055 CS
5 ug gE + 5 µg PHAD + 20 µg 1055 CS

FIGURE 17D



40 µg 1055 C.S + PHAD Liposomes
Dose 1
Reciprocal Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
$10^3$
$10^2$
$10^1$
****
****
5 µg gE + 5 µg PHAD
5 µg gE + 40 µg 1055 CS
5 µg gE + 5 µg PHAD + 40 µg 1055 CS

FIGURE 17E



80 µg 1055 C.S + PHAD Liposomes
Dose 1
Reciprocal Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
$10^3$
$10^2$
$10^1$
****
****
5 µg gE + 5 µg PHAD
5 µg gE + 80 µg 1055 CS
5 µg gE + 5 µg PHAD + 80 µg 1055 CS

FIGURE 18



Anti-gE IgG Endpoint Titers: Post Dose 2
Endpoint Titer (1/dilution)
10^7
10^6
10^5
10^4
10^3
5 µg gE alone
5 µg gE + 5 µg PHAD liposome
5 µg gE + 5 µg PHAD liposome + 5 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 10 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 20 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 40 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 80 µg 1055 CS
5 µg gE + 5 µg 1055 CS
5 µg gE + 10 µg 1055 CS
5 µg gE + 20 µg 1055 CS
5 µg gE + 40 µg 1055 CS
5 µg gE + 80 µg 1055 CS

FIGURE 19A



5 µg 1055 C.S + PHAD Liposomes
Dose 2
Endpoint Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
***
****
5 µg gE + 5 µg PHAD liposome
5 µg gE + 5 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 5 µg 1055 CS

FIGURE 19B



10 µg 1055 C.S + PHAD Liposomes
Dose 2
Endpoint Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
**
5 µg gE + 5 µg PHAD liposome
5 µg gE + 10 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 10 µg 1055 CS

FIGURE 19C



20 µg 1055 C.S + PHAD Liposomes
Dose 2
Endpoint Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
**
****
5 µg gE + 5 µg PHAD liposome
5 µg gE + 20 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 20 µg 1055 CS

FIGURE 19D



40 µg 1055 C.S + PHAD Liposomes
Dose 2
Endpoint Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
***
**
5 µg gE + 5 µg PHAD liposome
5 µg gE + 40 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 40 µg 1055 CS

FIGURE 19E



80 µg 1055 C.S + PHAD Liposomes
Dose 2
Endpoint Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
***
****
5 µg gE + 5 µg PHAD liposome
5 µg gE + 80 µg 1055 CS
5 µg gE + 5 µg PHAD liposome + 80 µg 1055 CS

FIGURE 20




L2 Endpoint Titers
Post Dose 1
Endpoint Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
$10^3$
$10^2$
$10^1$
PBS Alone
5 µg gE Alone
5 µg gE + L2
5 µg gE + 5 µg 1055 C.S
5 µg gE + 30 µg 1055 C.S
5 µg gE + 100 µg 1055 C.S
5 µg gE + L2 + 5 µg 1055 F.A
5 µg gE + L2 + 30 µg 1055 F.A
5 µg gE + L2 + 100 µg 1055 F.A
5 µg gE + L2 + 5 µg 1055 F.A + 20 µg PHAD
5 µg gE + L2 + 30 µg 1055 F.A + 20 µg PHAD
5 µg gE + L2 + 100 µg 1055 F.A + 20 µg PHAD
5 µg gE + 20 µg PHAD

FIGURE 21


L2 Endpoint Titers
Post Dose 2
Endpoint Titer
(1/dilution)
$10^7$
$10^6$
$10^5$
$10^4$
$10^3$
$10^2$
$10^1$
PBS Alone
5 µg gE Alone
5 µg gE + L2
5 µg gE + 5 µg 1055 CS
5 µg gE + 30 µg 1055 CS
5 µg gE + 100 µg 1055 CS
5 µg gE + L2 + 5 µg 1055 FA
5 µg gE + L2 + 30 µg 1055 FA
5 µg gE + L2 + 100 µg 1055 FA
5 µg gE + L2 + 5 µg 1055 FA + 5 µg PHAD liposomes
5 µg gE + L2 + 30 µg 1055 FA + 5 µg PHAD liposomes
5 µg gE + L2 + 100 µg 1055 FA + 5 µg PHAD liposomes
5 µg gE + 5 µg PHAD liposomes